Cargando…
Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
OBJECTIVE: This post hoc analysis in patients medically diagnosed with chronic migraine (CM) and medication‐overuse headache (MOH) evaluated reductions in the use of acute headache medication (AHM) and sustained changes in the diagnostic status of CM and MOH following eptinezumab treatment in the PR...
Autores principales: | Marmura, Michael J., Diener, Hans‐Christoph, Cowan, Robert P., Tepper, Stewart J., Diamond, Merle L., Starling, Amaal J., Hirman, Joe, Mehta, Lahar, Brevig, Thomas, Cady, Roger |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291601/ https://www.ncbi.nlm.nih.gov/pubmed/34551130 http://dx.doi.org/10.1111/head.14206 |
Ejemplares similares
-
Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
por: Cowan, Robert P., et al.
Publicado: (2022) -
Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023) -
Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult‐to‐Treat Migraine Headaches
por: Tepper, Stewart J., et al.
Publicado: (2019) -
Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020) -
Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine
por: Ford, Janet H., et al.
Publicado: (2020)